PC945 is the only anti-fungal that has been specifically developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, and to ensure a long duration of action and minimal systemic exposure.
PC945 is 30- to 100-fold more potent than voriconazole against Aspergillus fumigatus and exhibits minimal systemic bioavailability after inhaled administration and is intended for delivery by a standard, off-the-shelf nebulizer (Colley 2017).
PC945 has been used on a “special needs” basis in the UK in patients who have not responded to multiple standard-of-care (SOC) antifungal therapies, with remarkable results. As of January 2021, of the eleven (11) patients treated, positive clinical results were observed in nine (9) patients.
A Phase 3 study of PC945 for adults, who have limited or no alternative treatment options, for the treatment of invasive pulmonary aspergillus disease as part of a combined antifungal regimen will be initiated in 2022.
